https://orcid.org/0000-0001-9197-8060
References
- Moravan MJ, Fecci PE, Anders CK, et al. Current multidisciplinary management of brain metastases. Cancer. 2020;126(7):1390–1406. doi:10.1002/cncr.32714
- Soffietti R, Ahluwalia M, Lin N, Rudà R. Management of brain metastases according to molecular subtypes. Nat Rev Neurol. 2020;16(10):557–574. doi:10.1038/s41582-020-0391-x
- Feng E, Sui C, Wang T, Sun G. Temozolomide with or without radiotherapy in patients with newly diagnosed glioblastoma multiforme: a meta-analysis. Eur Neurol. 2017;77(3–4):201–210. doi:10.1159/000455842
- Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs. 2011;20(7):881–895. doi:10.1517/13543784.2011.580736
- Bulbul A, Forde PM, Murtuza A, et al. Systemic treatment options for brain metastases from non-small-cell lung cancer. Oncol Williston Park. 2018;32(4):156–163.
- Caraglia M, Addeo R. target therapy in brain tumours and metastases. Curr Cancer Drug Targets. 2012;3:18. doi:10.2174/156800912799277458
- Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29(3):447–463. doi:10.1007/s10555-010-9237-0
- Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci. 2018;213:236–247. doi:10.1016/j.lfs.2018.10.009
- Zhu XX, Ding YH, Wu Y, et al. Silibinin: a potential old drug for cancer therapy. Expert Rev Clin Pharmacol. 2016;9(10):1323–1330. doi:10.1080/17512433.2016.1208563
- Zappavigna S, Vanacore D, Lama S, et al. Silybin-induced apoptosis occurs in parallel to the increase of ceramides synthesis and miRNAs secretion in human hepatocarcinoma cells. Int J Mol Sci. 2019;20(9):2190. doi:10.3390/ijms20092190
- Guo S, Bai X, Liu Y, et al. Inhibition of TMEM16A by natural product silibinin: potential lead compounds for treatment of lung adenocarcinoma. Front Pharmacol. 2021;12:643489. doi:10.3389/fphar.2021.643489
- Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269(2):352–362. doi:10.1016/j.canlet.2008.03.053
- Binienda A, Ziolkowska S. the anticancer properties of silibinin: its molecular mechanism and therapeutic effect in breast cancer. Anticancer Agents Med Chem. 2020;20(15):1787–1796. doi:10.2174/1871520620666191220142741
- Prasad RR, Paudel S, Raina K, Agarwal R. Silibinin and non-melanoma skin cancers. J Tradit Complement Med. 2020;10(3):236–244. doi:10.1016/j.jtcme.2020.02.003
- Bosch-Barrera J, Menendez JA. Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev. 2015;41(6):540–546. doi:10.1016/j.ctrv.2015.04.008
- Wu M, Song D, Li H, et al. Negative regulators ofSTAT3signaling pathway in cancers. Cancer Manag Res. 2019;11:4957–4969. doi:10.2147/CMAR.S206175
- Li L, Zeng J, Gao Y, He D. Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs. 2010;19(2):243–255. doi:10.1517/13543780903533631
- Frenkel M. Is there a role for homeopathy in cancer care? Questions and challenges. Curr Oncol Rep. 2015;17(9):43. doi:10.1007/s11912-015-0467-8
- Bosch-Barrera J, Sais E, Cañete N, et al. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget. 2016;7(22):32006–32014. doi:10.18632/oncotarget.7900
- Wang C, Wang Z, Zhang X, et al. Protection by silibinin against experimental ischemic stroke: up-regulated pAkt, pmTOR, HIF-1α and Bcl-2, down-regulated Bax, NF-κB expression. Neurosci Lett. 2012;529(1):45–50. doi:10.1016/j.neulet.2012.08.078
- Priego N, Zhu L, Monteiro C, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24(7):1024–1035. doi:10.1038/s41591-018-0044-4
- Pérez-Sánchez A, Cuyàs E, Ruiz-Torres V, et al. Intestinal permeability study of clinically relevant formulations of silibinin in Caco-2 cell monolayers. Int J Mol Sci. 2019;20(7):1606. doi:10.3390/ijms20071606